How medical communicators can close the gap between rare disease breakthroughs and the patients who need them

The rare disease landscape is unlike any other

For most patients with a rare disease, the road to diagnosis is long, winding, and often lonely. Rare diseases have small patient populations, which means they are easy to miss, easy to misdiagnose, and rarely top of mind for most clinicians. Patients frequently bounce between healthcare providers and health systems for years before anyone puts a name to what they are experiencing. Even then, an established care plan may not exist.

Further, the evidence base supporting a new therapy in rare disease is limited by small patient populations. Each publication, registry, trial, center, and expert voice on the disease can have an outsized impact on clinical understanding for years to come.

If the scientific narrative is unclear, inconsistent, or disconnected from patients’ lived experience, it can have downstream consequences that are far-reaching: delayed diagnosis, missed referrals, and therapies that never reach the patients who need them.

It takes more than a great therapy and compelling data to reach EVERY PATIENT POSSIBLE. Medical Affairs teams must build field readiness, drive education, interpret evidence, and forge strong connections between healthcare providers and patients in a unique way.

Forget launch readiness, think landscape readiness

Traditional Medical Affairs approaches are built around the launch of a newly approved drug. But in rare disease, the clinical ecosystem itself often isn’t ready for traditional launch support: disease definitions are still evolving, treatment pathways are unclear, and clinical awareness can be patchy.

That’s why shifting from launch readiness to landscape readiness is key in rare disease. Medical Affairs teams need to build the foundation— disease awareness, education, stakeholder alignment—well before a therapy is approved. It’s a longer runway, but it’s necessary for healthcare stakeholders to access, understand, and act on new treatments when they arrive.

Landscape readiness in rare disease has five key parts: knowing the ecosystem, centering the patient, making limited evidence work, telling a consistent story, and planning for reach.

Know the ecosystem

Rare disease doesn’t have a typical stakeholder map. The ecosystem has distinct but overlapping roles that are each essential to determining whether a patient with a rare disease is identified and has access to care.

Engaged stakeholders already have a deep understanding of the disease, patient journey, and knowledge gaps. These include groups that Medical Affairs teams traditionally interact with: specialists, genetic counselors, diagnosticians, patient advocates, caregivers, and key opinion leaders (KOLs).

Access stakeholders such as care navigators, hospital system administrators, policymakers, and payers may not yet be engaged in the disease but nevertheless hold critical insights into determining how patients can reach and remain in care. These stakeholders should be identified early so they can shape and validate the scientific narrative as it is being built.

Generalist stakeholders who do not specialize in rare diseases and require support in identifying them must also be understood and mapped. A primary care physician may go 30 years without seeing a particular rare disease, but they need to be able to recognize it if and when it does present. The generalist who spots an unusual symptom pattern and knows how to refer is just as important as the specialist who confirms the diagnosis.

These groups rarely attend the same conferences, read the same journals, or have the same day-to-day priorities. Understanding how specialist knowledge needs to translate into access decisions and generalist practice is key to developing  practical, accessible tools to support every point on the patient journey.

Center the patient

For patients and families living with a rare disease, the distance between clinical endpoints and real life can be huge. A biomarker might be scientifically meaningful but hard for a parent to connect to their child’s prognosis. A trial endpoint might be statistically valid, but not represent an outcome that actually changes daily life, like function, independence, or caregiver burden. And the practical realities of living with a rare disease—travel to specialist centers, time off work, insurance battles, emotional exhaustion—are often invisible to clinicians, but central to the patient experience.

Medical Affairs teams can bridge that gap through advisory boards, advocacy partnerships, disease journey research, and endpoint discussions. Every rare disease community is different: some have highly organized advocacy networks, while others have no central hub at all. The approach needs to fit the community and strengthen advocacy where needed.

Make the limited evidence work

In rare diseases, data are naturally limited. Studies often involve small, geographically dispersed populations with widely varying presentations. That’s not a flaw, but the nature of the space.

Rather than allowing limited evidence to create paralysis, , Medical Affairs teams can bring together what is known,  clearly acknowledge what is not known and prioritize the evidence gaps that matter most

Additionally, different stakeholders need different things: Clinicians want biological plausibility and a sense of how individual patients might respond, payers want evidence of value and durability, and patients and caregivers want to know what this means for their lives. A structured approach to evidence interpretation speaks to all of them.

Tell a consistent story

All of this work needs to support a single, consistent scientific narrative that can be used effectively across publications, congress presentations, medical science liaison conversations, digital resources, and patient advocacy initiatives.

The same expert health care professional might contribute to a publication, shape referral pathways, and be active in the patient community. Inconsistency doesn’t just create confusion, it actually erodes trust. And in a small, interconnected community, word travels fast.

Plan to reach every patient possible, and be clear about what finding them means

Most Medical Affairs teams understand that an integrated communications plan requires sequenced touchpoints that build on one another, rather than compete for stakeholders’ attention. What is less widely agreed upon in rare disease is when to begin this work.

Early stakeholder engagement, ideally in Phase II or early Phase III, builds the strongest KOL relationships, educates healthcare providers, and enables faster clinical trial recruitment, supporting a stronger regulatory position and market readiness. Further, strengthening provider awareness is a powerful tool to shorten the patient’s diagnostic odyssey, ending years (or even decades) of uncertainty, opening the door to clinical trials, stopping inappropriate treatment, enabling access to disease-specific support, and connecting patients to a community.

The harder and more important question is how awareness is framed. Does it honestly reflect the current state of science? Awareness campaigns must be cautious not to conflate diagnosis with the availability of effective treatments—knowing how to diagnose a disease is not the same thing as knowing how to treat it. That gap, if left unacknowledged, is where trust breaks down.

There’s no universal answer. The right approach depends on the disease, the evidence, regulatory considerations, KOL relationships, the patient community, and the existing level of clinical awareness.  What’s clear is that the decision of when and how to start raising disease awareness should always consider what serves patients. Medical Affairs teams are well-placed to support earlier diagnosis and greater clinical recognition while remaining clear about what the science can and cannot yet deliver.

Ready to make sure your rare disease breakthrough reaches patients?

Simply put, the goal of a Medical Affairs team working in rare disease is to help clinicians recognize symptoms, know when to test or refer, understand where to send patients for specialized care, and feel confident in having informed conversations with patients and families.

Rare disease strategy isn’t just about scientific expertise. It’s about connecting evidence, stakeholder insights, and patient needs into education, tools and connections that help the clinical community to take action.

Avalere Health partners with Medical Affairs teams to build the scientific foundation and engagement plans that get therapies to the patients who need them.

Because no patient should be too rare to reach.